Management of Acute Complicated Diverticulitis: An Assessment of Current Practices
1 other identifier
observational
208
1 country
1
Brief Summary
Acute complicated diverticulitis (ACD) is a frequent surgical emergency that can be life-threatening. It encompasses various clinical entities, including colonic perforations, abscesses (Hinchey II), fistulas, and purulent or fecal peritonitis (Hinchey III/IV). Historically, the Hartmann procedure (HP) was established as the standard of care for diffuse peritonitis, particularly in frail patients. However, this intervention is associated with high rates of permanent stomas, long-term complications, and impaired quality of life. Over the past decade, several randomized controlled trials (RCTs) have compared HP with sigmoid resection and primary anastomosis (PA), sometimes combined with a diverting ileostomy. Results from these studies, notably the LADIES and DIVERTI trials, indicate that in hemodynamically stable and immunocompetent patients, PA is associated with superior functional outcomes, fewer late complications, and higher stoma reversal rates. Other minimally invasive approaches, such as laparoscopic peritoneal lavage for Hinchey III, have also been explored, showing promise in reducing stomas and reinterventions. However, their efficacy relies on stringent patient selection, and their use is not recommended by current guidelines (e.g., HAS 2017) due to higher reintervention rates. Recent epidemiological data suggest a trend toward reducing emergency surgical interventions in favor of more conservative strategies in selected cases, such as initial medical management followed by elective surgery. In this context of diversifying therapeutic options, choosing the optimal treatment requires a delicate balance between efficacy, morbidity, mortality, quality of life, and long-term preservation of intestinal function. Despite these advances, several questions remain, particularly regarding patient selection criteria and the real-world long-term impact of these interventions. A potentially underestimated factor is the role of the operator, as a significant portion of emergency cases (nights and weekends) are handled by surgeons in training. Primary Objective: To provide a comprehensive overview of current management strategies for acute complicated diverticulitis by identifying preferred therapeutic modalities (conservative management, emergency surgery, delayed surgery) at the HUB (Hôpital Universitaire de Bruxelles). Secondary Objectives: To evaluate the adherence of these therapeutic approaches to international guidelines. To identify clinical and context-specific predictive factors influencing the choice of therapeutic strategy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2026
CompletedFirst Submitted
Initial submission to the registry
May 11, 2026
CompletedFirst Posted
Study publicly available on registry
May 22, 2026
CompletedMay 22, 2026
May 1, 2026
4 months
May 11, 2026
May 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Distribution of management strategies for acute complicated diverticulitis.
Percentage of patients treated by each of the following strategies: exclusive medical treatment, radiological drainage, immediate emergency surgery, rescue surgery following medical failure, or elective surgery.
From hospital admission up to 10 years (end of study period).
Secondary Outcomes (7)
Surgical Procedure Type (Hartmann Procedure vs. Primary Anastomosis) based on Hinchey Classification and Clinical Status.
Through study completion, an average of 14 days (duration of index hospitalization).
Success rate of conservative treatment for complicated diverticulitis.
During index hospitalization (average of 12.4 days).
Post-operative morbidity and mortality.
30 days post-surgery.
Stoma reversal rate.
Up to 10 years.
Evolution of the Rate of Laparoscopic Approach.
Perioperative (during initial surgery).
- +2 more secondary outcomes
Eligibility Criteria
Patients older than 18 years who were treated for acute complicated diverticulitis between January 1, 2015 and December 31, 2024 at Erasme Hospital and Institut Jules Bordet.
You may qualify if:
- Patients presenting with a first episode or recurrence of acute complicated diverticulitis.
- CT scan confirmation of a Hinchey stage ≥ Ib (including stages Ib, II, III, and IV) at admission.
- Initial management performed within the HUB (Hôpital Universitaire de Bruxelles) network.
- Hospital admission between January 1, 2015, and December 31, 2024.
You may not qualify if:
- Uncomplicated acute diverticulitis, defined by a CT scan Hinchey stage of 0 or Ia.
- Patients in whom the diagnosis of acute diverticulitis was ultimately ruled out during medical chart review.
- Patients whose initial management occurred at another hospital facility (outside the HUB network).
- Incomplete medical records preventing the reliable extraction of clinical or follow-up data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut Jules Bordet
Anderlecht, Brussels Capital, 1070, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 11, 2026
First Posted
May 22, 2026
Study Start
December 1, 2025
Primary Completion
March 30, 2026
Study Completion
March 30, 2026
Last Updated
May 22, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared in order to protect patient confidentiality and comply with European data protection regulations (GDPR) and institutional privacy policies.